Pain Assessment and Treatment Guidelines across Addiction Status

Lacy A. Fabian1*, Meridith H Thanner1 and Katherine Kim2

1Health and Analytics, Battelle, Baltimore, MD 21209, USA
2School of Pharmacy, Notre Dame of Maryland University, Baltimore, USA

*Corresponding author: Lacy A. Fabian, Health and Analytics, Battelle; Baltimore, MD 21209, USA, Tel: +1-410-372-2731; Fax: +1-614-485-0661; E-mail: FabianL@Battelle.org

Received date: March 14, 2014; Accepted date: April 23, 2014; Published date: April 30, 2014

Abstract

Chronic pain is one of the most widespread and costly complaints facing healthcare today. In developing appropriate care plans for managing chronic pain it is critical to adequately assess risk factors that may alter the course of the pain. Notably, addiction operates along many of the same pathways as pain and can serve as a moderating factor in caring for those in pain (i.e., considering medications to prescribe for the management of pain in those with an active addiction) or a mediating factor whereby a new addiction develops in the course of managing the pain. This review examines addiction risk assessment tools specifically in the realm of alcohol, opioid use, and tobacco, which can be used in developing chronic pain care plans. Though the importance of assessing risk factors associated with addiction is well recognized, given the implications for the management of chronic pain, the means for adequately utilizing the assessments are limited by a lack of standardization and even barriers in the healthcare setting, such as time with which to perform the assessments. Efforts to develop psychometrically strong risk assessments tailored for use in various healthcare settings that allow for stratification into levels of risk and also employ strategies beyond mere subjective self-report are needed. As pain is such a prevalent experience and is considered a vital sign of health status, appropriate pain management is critical to managing healthcare costs and preventing undue stress on individuals, particularly those with various addictions.

Keywords: Pain assessment; Addiction; Treatment guidelines; Substance use disorder; Tobacco; Alcohol; Opioids

Introduction

Chronic pain is one of the most widespread complaints in healthcare settings [1]. It is both a persistent and costly concern, especially among those with a substance use disorder (SUD). Among this group, however, the coexistence of these disorders often remains inadequately assessed and treated, often because medical providers are ill equipped to evaluate substance use and abuse in pain patients [2]. Prevalence of chronic pain in this group is estimated to be higher than in the general population [3,4] with more than a third of the population reporting comorbid pain and substance abuse. Potter and colleagues [5] found, for example, in a multi-site treatment outcome study that one forth to one third of people seeking treatment for SUDs experienced moderate to severe chronic pain in the previous year. Their findings show the presence of a sizable proportion of patients with both SUD and pain who would benefit from the use of a valid risk assessment in developing their pain management care plan.

Chronic Pain Experience in Addiction

Substance use and pain are interrelated, with each experience influencing the persistence and treatment of the other [4]. Dependence on alcohol, drugs, and tobacco, for example, and chronic pain share common neural circuits, with the same pathways and brain regions, such as the anterior cingulate cortex [6], that regulate addiction also mediating chronic pain (Figure 1). It is anticipated that pain could affect substance use patterns while dependence conversely could influence pain sensitivity [7]. Thus, effective management of either condition requires that issues associated with both be simultaneously addressed [3,8].

Given the interplay between the pathways that regulate addiction and pain, dissecting “true pain from drug-seeking behaviour” to properly manage pain in patients with a comorbid SUD can be challenging [9]. There is great overlap in physiologic states between addiction and pain in patients with SUD, and this can affect how pain is processed and tolerated, as having both conditions coexist can lead to a reorganization of the brain’s baseline perceptual pathways. SUD patients, for instance, have been found to have levels of pain tolerance different from, greater than or less than, those not with an addiction [4]. This line of research related to understanding the neuro-biologic interactions between chronic pain and SUD is still developing and a review of current practice and guidelines in support of producing more effective care plans for managing chronic pain is warranted.

Chronic Pain Experience in Addiction

Substance use and pain are interrelated, with each experience influencing the persistence and treatment of the other [4]. Dependence on alcohol, drugs, and tobacco, for example, and chronic pain share common neural circuits, with the same pathways and brain regions, such as the anterior cingulate cortex [6], that regulate addiction also mediating chronic pain (Figure 1). It is anticipated that pain could affect substance use patterns while dependence conversely could influence pain sensitivity [7]. Thus, effective management of either condition requires that issues associated with both be simultaneously addressed [3,8].

Given the interplay between the pathways that regulate addiction and pain, dissecting “true pain from drug-seeking behaviour” to properly manage pain in patients with a comorbid SUD can be challenging [9]. There is great overlap in physiologic states between addiction and pain in patients with SUD, and this can affect how pain is processed and tolerated, as having both conditions coexist can lead to a reorganization of the brain’s baseline perceptual pathways. SUD patients, for instance, have been found to have levels of pain tolerance different from, greater than or less than, those not with an addiction [4]. This line of research related to understanding the neuro-biologic interactions between chronic pain and SUD is still developing and a review of current practice and guidelines in support of producing more effective care plans for managing chronic pain is warranted.

Chronic Pain Experience in Addiction

Substance use and pain are interrelated, with each experience influencing the persistence and treatment of the other [4]. Dependence on alcohol, drugs, and tobacco, for example, and chronic pain share common neural circuits, with the same pathways and brain regions, such as the anterior cingulate cortex [6], that regulate addiction also mediating chronic pain (Figure 1). It is anticipated that pain could affect substance use patterns while dependence conversely could influence pain sensitivity [7]. Thus, effective management of either condition requires that issues associated with both be simultaneously addressed [3,8].

Given the interplay between the pathways that regulate addiction and pain, dissecting “true pain from drug-seeking behaviour” to properly manage pain in patients with a comorbid SUD can be challenging [9]. There is great overlap in physiologic states between addiction and pain in patients with SUD, and this can affect how pain is processed and tolerated, as having both conditions coexist can lead to a reorganization of the brain’s baseline perceptual pathways. SUD patients, for instance, have been found to have levels of pain tolerance different from, greater than or less than, those not with an addiction [4]. This line of research related to understanding the neuro-biologic interactions between chronic pain and SUD is still developing and a review of current practice and guidelines in support of producing more effective care plans for managing chronic pain is warranted.
Figure 1: The pathways of pain (Figure originally presented elsewhere) evidence significant neuronal overlap with addiction processes including the limbic forebrain’s system comprised notably of the hippocampus and anterior cingulate cortex that is connected with the amygdala, nucleus accumbens, insula cortex and hypothalamus.

### Pain Assessment Guidelines

In addition to better identifying how to most effectively and efficiently assess and treat the SUD population also presenting with chronic pain, a gap in understanding exists in how such assessments and care plans should be modified to improve outcomes given individual patient characteristics such as age, gender, race/ethnicity, etc. Despite a recognition by researchers and practitioners that pain and responses to pain vary by such factors as gender, age, and other health/bio-psychosocial factors and thus, that the consideration of individual characteristics matters [3,10-14] – when looking at pain and SUD independently as well as together – research, practice, and implementation has been mixed.

A better understanding of these mechanisms overall, as well as by individual differences, is needed to inform assessments and interventions designed to alleviate both pain as well as treat coexisting addiction. In particular, an understanding of the various pathways between pain and addiction (addiction anteceding or following the onset of chronic pain) and how these may differ based on individual characteristics, has implications for how best to assess and then treat these comorbid conditions within different groups of patients. The literature to date is mixed [4,15-17] and the present review examines the current state of the field, including a review of prevalence rates, assessment tools, and treatment guidelines for alcohol, opioid and tobacco addiction’s implications for chronic pain within a bio-psychosocial framework (Table 1).

<table>
<thead>
<tr>
<th>Screening Tools</th>
<th>Assessment</th>
<th>Scoring</th>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opioids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening Tool for Addiction Risk (STAR) [2]</td>
<td>Self-administered survey tool to help identify risk for addiction in chronic pain patient receiving opioids treatment</td>
<td>14 true-or-false questions</td>
<td>Self-administered questionnaires</td>
<td>Does not detect active substance abuse in patient with chronic pain</td>
</tr>
<tr>
<td><strong>Pain Medication Questionnaire (PMQ) [40]</strong></td>
<td>An ongoing tool to identify patients on a range of potential risk factors through self-reports of addiction related behaviors</td>
<td>26 questions represented on a 5-point Likert scale format</td>
<td>Good reliability and predictive validity</td>
<td>It is not a diagnostic tool</td>
</tr>
<tr>
<td><strong>Screening and Opioid</strong></td>
<td>A self-reported tool to predict aberrant medication related</td>
<td>14-item self-reported questionnaire</td>
<td>N/A</td>
<td>Scoring difficulties due to only 14-items</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Assessment for Patient with Pain (SOAPP)</th>
<th>behaviors among chronic pain patient</th>
<th>Patient’s easily categorized into high-risk category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screener and Opioid Assessment for Patient with Pain – Revised (SOAPP-R) [48]</td>
<td>A risk assessment tool to help predict possible opioid abuse in patient with chronic pain</td>
<td>24-item self-reported questionnaire</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Greater sensitivity and specificity to prediction score</td>
</tr>
<tr>
<td>Opioid Risk Tool (ORT) [47]</td>
<td>A self-administered risk assessment tool to help predict aberrant behaviors while on opioids therapy to manage chronic pain</td>
<td>Potential risk factors were awarded a specific point value based on responder’s sex.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The total score used to stratify patient into three risk groups: Low (0-3), Moderate (4-7), and High (&gt; 8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Greatly distinguish risk between high and low risk patients</td>
</tr>
<tr>
<td>Diagnosis, Intractability, Risk, Efficacy (DIRE) Score [34]</td>
<td>A risk assessment tool to help identify chronic pain patients at risk for addiction while receiving opioids treatment, and help assess whether patient will remain compliant to long-term opioids therapy</td>
<td>Scoring criteria consist of four main factors that are broken into four subcategories</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scoring: Not a suitable candidate (7-13), Good candidate (14-21)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Distinguishable risk groups between high and low risk patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prospective follow up of cohort for over 12 months</td>
</tr>
<tr>
<td>Alcohol</td>
<td>CAGE Assessment [48]</td>
<td>A screening tool for alcohol use disorders (AUD)</td>
</tr>
<tr>
<td>Scoring: Probable alcoholism (2+)</td>
<td>Completion Time: 30 seconds</td>
<td>Widely varying sensitivity based on the cut-off point used</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>Simple and easy to use</td>
<td>Sensitivity low in elderly and psychiatric population</td>
<td></td>
</tr>
<tr>
<td>Identify lifetime prevalence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adopted version to include risk for drug abuse: CAGE-AID</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Michigan Assessment Screening Test (MAST)** [48]

A screening tool for alcohol abuse/dependence and hazardous drinking

**Alcohol Use Disorder Identification Test (AUDIT)** [48]

A screening tool for alcohol abuse/dependence and hazardous drinking

<table>
<thead>
<tr>
<th>Scoring: Indicate alcohol abuse/dependence (6+)</th>
<th>High sensitivity</th>
<th>Longer completion time: 5 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>High specificity with standard cut-off at 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Different versions of the tool to assess elderly population: MAST-G, SMAST-G</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scoring: Indicate alcohol abuse/dependence (8+)</th>
<th>Completion Time: 2-3 minutes</th>
<th>Identify active and current alcohol abuse</th>
</tr>
</thead>
<tbody>
<tr>
<td>New version AUDIT-5: shown to outperform AUDIT and CAGE in elderly and psychiatric patients</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Table 1: Summary of initial screening tools used for risk assessment to establish addiction status in individuals presenting with chronic pain |

**Alcohol addiction**

Prevalence: Based on findings from the National Epidemiologic Survey on Alcohol and Related Conditions Prevalence, prevalence of lifetime and 12-month alcohol abuse is 17.8% and 4.7% respectively and prevalence of lifetime and 12-month alcohol dependence is 12.5% and 3.8%. For respondents who have lifetime alcohol dependence, only 24.1% seek treatment for alcohol dependence. Additionally, respondents with lifetime alcohol dependence were likely to have fewer comorbid disabilities (social, emotional, or mental) compared to those who have never received treatment [18]. In another study, Sheu and colleagues [16] found that patients in an alcoholic outpatient treatment program were more likely to cite physical pain compared to other factors as the impetus for alcohol abuse during the prior three months. Of this group, only 13% were receiving any form of care for their chronic pain, though 72% expressed an interest in “treatment”. Given the association between chronic pain and alcohol abuse, and the belief that the majority of chronic pain problems will not resolve while there is ongoing alcohol (or other drug) abuse [3,19], the ability for physicians to identify and simultaneously manage co-occurring pain and alcohol addiction is critical. With so few patients receiving adequate pain management, findings further support the need to better assess and address pain problems in this substance abusing population and to engage the healthcare team.

Treatment guidelines: It is the consensus of researchers that until alcohol abuse is brought under control, treatment of chronic pain will be ineffective. Once a patient presenting with chronic pain is assessed as having a coexisting SUD, it is recommended that s/he first be referred to an addiction treatment provider for treatment of their alcohol dependence while continuing under the care of their primary care physician for pain management [3]. However, most primary care physicians are ill equipped to adequately assess this, or any other, substance use disorder due to lack of available time to conduct screenings, knowing whether a screening is warranted for the particular patient, knowing the best screener to use, and administering the screener in a way that is cost effective [20]. The culmination of these barriers can result in missed detection of an alcohol dependence problem altogether, thus further complicating treatment of chronic pain [21,22]. Moreover, individual characteristics with respect to the presentation, assessment, and treatment of both pain and alcohol addiction must be considered.
Assessment tools: When working with chronic pain patients, it is important to determine as early as possible in the development of a pain management care plan whether coexisting alcohol dependence exists. At present, the authors were unable to identify a single assessment tool that accomplished this end specifically for chronic pain patients. As such, practitioners must rely on a combination of assessment tools to help fully characterize an understanding of their patient’s condition [3]. Furthermore, as part of conducting the overall pain assessment, including SUD assessment, often based on patient self-reports, collected information is most beneficial when corroborated with other sources of information such as medical records, family interviews, lab work, etc. [23]. Without a valid assessment tool, it is difficult for a primary care physician to identify a patient with a coexisting SUD. For identifying the 'unobvious' alcohol dependent patient presenting with chronic pain, the CAGE (Cut-down, Annoyed, Guilty, Eye-Opener), consisting of only four questions, has been shown to be a valid and reliable screening tool for detection of problem alcohol use in such populations as general practice medical patients (inpatient and ambulatory), surgical inpatients, and psychiatric inpatients [24].

Evidence and recommendations: Broadly, research has found that patients who present with chronic and severe pain are significantly more likely to also present with a comorbid SUD. Shue et al. [16], for example, further found that patients with coexisting pain and SUD also report that their physical pain led to their alcohol (and other substance) use. A few studies have examined comorbid chronic pain and alcohol abuse with a specific focus on examining individual characteristics. In an older investigation of patients with chronic lower back pain, compared on age, sex, civil status, and income to matched control groups, investigators found that alcohol abuse was significantly more frequent among the male patients [25]. In a more recent examination, Parks et al. [26], in an on-going study of phenotypes of alcohol dependence among Alaska Natives by gender, found that male and female subjects reported similar experiences with alcohol-related health problems, though women reported more chronic pain related complaints and complications. These reports of more pain symptoms by women, in addition to increased use of and increased negative general health consequences compared with men in this alcohol dependent sample, suggests additional considerations for treatment planning and intervention [26].

Opioid addiction

Prevalence: Misuse of opioids in the United States and abroad has reached epidemic proportions that is attributed to their availability and misconceptions on proper use [1,27,28] with estimates ranging from 14% to 19% [29]. Given the prevalence of chronic pain, it poses a challenge to clinicians of just how to provide pain relief and accurately account for existing addiction or addictive tendencies.

Treatment guidelines: Common guidelines with the most evidentiary support show a need for caution at doses greater than 90-200 mg of morphine equivalents per day, fentanyl patch risks, 25-50% dose reduction when switching opioids, as well as risk assessment tools, treatment agreements and urine drug assessments [30]. Treatment for co-occurring chronic pain and opioid use disorders only receives general guidance on what constitutes a valid risk assessment tool [27] with standard International Classification of Disease (ICD-10) criteria being the "gold standard" [29] focusing on tolerance, physical dependence, and withdrawal [1]; the criteria, however, may also need to include preoccupation with obtaining opioids, loss of control over use, and adverse consequences of use [1].

Assessment tools: Screening tools do exist that focus on the occurrence of prior substance abuse; however, this can fall short when the risk of developing a new opioid addiction during management of chronic pain is estimated between 3-12% [27]. A recent study comparing Portenoy’s criteria with the ICD-10 [29,31] found factors such as younger age, alcohol use, and higher prescription doses of opioids to be significant risk factors for opioid addiction when using either criteria. Other studies have also found tobacco use to be risk factor for substance abuse generally, and non-medical opioid abuse specifically [2,32]; depression and anxiety, in addition to tobacco use, have also been found predictive of opioid addiction [33]. Others [31] have combined existing assessment tools focusing on past drug and alcohol use, family and personal history of use, abuse and psychosis; aberrant behavior; and other pain treatment methods in order to develop a rapid assessment tool in ambulatory clinics, with the consistent finding that of primary importance was a space for clinicians to summarize overall risk level [32,33] and also tools to assess likely compliance such as the Diagnosis, Intractability, Risk and Efficacy (DIRE) score [34]. Additionally, the type of pain itself may also be relevant to risk of addiction with more severe illnesses, inability to easily access medications, and persistence in pursuing accurate treatment and diagnosis being associated with a lower prevalence of an SUD [15].

Tobacco addiction

Prevalence: Although the overall smoking prevalence has declined from 2005 (20.9%), there are still an estimated 42.1 million (18.1%) adults who smoke in the United States. Smoking related deaths accounts for approximately 480,000 a year, or one in every five, while smoking related complications such as lung cancer and COPD is prevalent in about 16 million people in the U.S. [39] Given the current prevalence of smoking and the growing popularity of other tobacco products, it becomes more urgent to understand how tobacco dependence may impact the management of chronic pain or increase risk for other substance; namely, opioid, abuse.

Treatment guidelines: Treatment guidelines for chronic pain across various organizations such as the American Chronic Pain Association (ACPA) and Institute of Medicine (IOM) focus more on smoking cessation as a means for better pain control and management. However, these guidelines do not recognize tobacco dependence as a possible predictor or risk factor to help identify or potentiate opioid

abuse in chronic pain patients with or without addictive tendencies, as recent research may suggest is warranted. Several studies suggest that heavy smoking in chronic pain patients were indicative of future SUDs or addiction to opioids [17,40,41], while other studies suggest tobacco abuse as a predictor for substance abuse [42].

Assessment tools: Although there are many screening tools available to help assess future risk for addiction, many of these tools focus on personal and family history of abuse to alcohol and prescription and illicit drugs. Seemingly often these tools do not assess smoking history or status of the individual. Thus, screening tools for addiction potential. Healthcare facilities at all points of a patient smoking history or status of the individual. Thus, screening tools for recent research may suggest is warranted. Several studies suggest that responses to pain may pose a risk of over or under utilization of physiologic and pathways. Chronic smokers may present with higher sensitivity to pain, [16], yet, a risk assessment tool validated in the Michigan Alcohol Screening Test (MAST) and CAGE to assess smoking history of an individual and prior treatment to substance abuse. Results show that smoking related questions listed in STAR help identify pain patients with substance abuse and addictive tendencies from pain patients without history of substance abuse. Furthermore, it is evident that prior treatment for SUD was as a potential risk factor in patients receiving opioids for chronic pain [42].

Evidence and recommendation: Current evidence suggests that nicotine exerts its effects on various neurobiological systems, which may alter pain perception and endogenous pain regulatory mechanisms. Chronic smokers may have a diminished physiological response to various stressors, often due to the absence of certain stress-induced analgesia and relatively low release of cortisol and ACTH, during high times of stress when compared to non-smokers. Due to this, chronic smokers may present with higher sensitivity to pain, which may often manifest as higher pain ratings [43]. These “blunted” responses to pain may pose a risk of over or under utilization of opioids or other medications to manage chronic pain. The lack of current screening tools that assess tobacco addiction in chronic pain populations, and the growing body of evidence that reveals smoking as a predictor or risk factor to substance abuse or opioid addiction, it is therefore recommended that inquiries of tobacco use be taken into account when developing risk assessment tools for chronic pain populations.

Conclusion

Alcohol, opioid, and tobacco use addictions have implications in the management of chronic pain, and their interrelation is an area in need of more standardized risk assessment protocols that move beyond mere self-report. Alcohol use can moderate and mediate the pain experience [16], yet, a risk assessment tool validated in the chronic pain population is not readily available. Likewise, not only are the long-term effects of opioid use not well understood [32,33,44], there is also concern of noncompliance and under-reported use [45]. Furthermore, tobacco use appears a critical addition to a risk assessment tool, given the implications for the pain experience and addiction potential. Healthcare facilities at all points of a patient treatment cycle such as ambulatory clinics, primary care, and pharmacies need access to tailored risk assessment tools that allow for summative assessment and stratification into risk levels. Ideally, such risk assessment tools will provide clinicians with rapid assessment tool, given the implications for the pain experience and addiction potential. Healthcare facilities at all points of a patient treatment cycle such as ambulatory clinics, primary care, and pharmacies need access to tailored risk assessment tools that allow for summative assessment and stratification into risk levels. Ideally, such risk assessment tools will provide clinicians with rapid assessment options, with validated approaches, that rely on more than self-report and questions that recognize the overlap in underlying neural physiology and pathways.

References


